Welcome to our dedicated page for Sol Gel Tech news (Ticker: SLGL), a resource for investors and traders seeking the latest updates and insights on Sol Gel Tech stock.
Sol-Gel Technologies Ltd. (NASDAQ: SLGL) is a dermatology company whose news flow centers on clinical trial progress, regulatory milestones, licensing transactions and financial updates related to its topical drug products and pipeline. The company developed TWYNEO, a fixed-dose combination cream for acne vulgaris, and EPSOLAY, a benzoyl peroxide cream for inflammatory lesions of rosacea, and continues to report on ex-U.S. approvals and commercialization agreements for these products.
Recent Sol-Gel news highlights include updates on its pivotal Phase 3 clinical trial of SGT-610 (patidegib gel 2%) for Gorlin syndrome, including completion of patient enrollment and expectations for future top-line results. The company also issues releases on exploratory work to extend SGT-610 into high-frequency basal cell carcinoma and on compassionate-use cases in patients with PTCH1-mutated lesions. For SGT-210, a topical erlotinib candidate for Darier disease and other rare hyperkeratinization disorders, Sol-Gel has reported on Phase 1b proof-of-concept data, trial design decisions and plans for feasibility studies in additional indications.
Investors following SLGL news will also find announcements on Health Canada’s approval of EPSOLAY, new license agreements with partners such as Searchlight Pharma, Viatris and regional distributors, and a product purchase agreement with a subsidiary of Mayne Pharma for U.S. rights to EPSOLAY and TWYNEO. Periodic financial results releases provide detail on revenue from licensing and royalties, research and development spending on SGT-610 and SGT-210, cash runway expectations and capital market developments such as the company’s reverse share split and Nasdaq listing status.
This news page aggregates these company-issued updates and related coverage, making it easier to track Sol-Gel’s clinical, regulatory and commercial milestones over time for its dermatology portfolio and rare disease pipeline.
Sol-Gel Technologies (Nasdaq: SLGL) announced its participation in two virtual conferences: the LifeSci Partners 11th Annual Corporate Access Event on January 5, 2022, featuring 1-on-1 meetings, and the H.C. Wainwright BioConnect 2022 Healthcare Conference, with a corporate presentation webcast available from January 10-13, 2022. The company focuses on developing topical drug products for skin diseases, leveraging its microencapsulation technology. The FDA is set to conduct a pre-approval inspection for its product EPSOLAY in February 2022, aiming for commercialization with Galderma.
Sol-Gel Technologies (NASDAQ: SLGL) announced that the FDA intends to conduct a pre-approval inspection of the production site for its drug EPSOLAY during the week of February 14, 2022. EPSOLAY is under FDA review for treating inflammatory lesions of rosacea in adults. CEO Alon Seri Levy expressed optimism about this development, as previous inspection timelines had been delayed due to COVID-19. The drug's technology involves encapsulating benzoyl peroxide in microcapsules for gradual release, supported by patents until 2040.
Sol-Gel Technologies (SLGL) reported a profitable third quarter with total revenues of $8.8 million, net income of $1.3 million, and an EPS of $0.06. Key revenue drivers included a $3.5 million milestone payment from Galderma linked to FDA approval of TWYNEO® and a $4.0 million upfront payment. Sol-Gel secured a new agreement with Padagis that will yield $21 million over 24 months, allowing them to focus on development. Their cash runway extends through 2023, bolstered by partnerships and sales of generics.
Sol-Gel Technologies (Nasdaq: SLGL) announced its participation in the Jefferies London Healthcare Conference on November 16-17, 2021. Dr. Alon Seri-Levy, CEO, will present live on November 16 from 8:00 to 8:35 AM GMT. The presentation will discuss Sol-Gel’s focus on developing treatments for skin diseases, including the FDA-approved TWYNEO for acne and EPSOLAY, which is pending FDA action. The company is also advancing early-stage candidates targeting other dermatologic conditions.
For more details, visit www.sol-gel.com.
Sol-Gel Technologies (Nasdaq: SLGL) announced a new agreement with Padagis, securing $21 million over 24 months by transferring rights to two marketed generic drugs and eight unapproved generic programs. The company will retain collaboration rights for two valuable generic programs. This agreement is expected to extend Sol-Gel's cash runway through at least Q4 2023. Sol-Gel focuses on advancing its innovative pipeline and supporting Galderma in launching TWYNEO and EPSOLAY, pending FDA approvals.
Sol-Gel Technologies, Ltd. (Nasdaq: SLGL) has announced its participation in the virtual Cantor Global Healthcare Conference from September 27-30, 2021. During this event, Dr. Alon Seri-Levy and CFO Gilad Mamlok will engage in a fireside chat discussion on September 30, starting at 10:40 a.m. ET. The discussion will be available on demand, and a replay can be accessed for 30 days. Sol-Gel focuses on developing topical dermatology treatments, leveraging proprietary technologies for products like TWYNEO and EPSOLAY. For more information, visit their official website.
Sol-Gel Technologies, Ltd. (Nasdaq: SLGL) announced its participation in H.C. Wainwright’s 23rd Annual Global Investment Conference from September 13-15, 2021. The event will feature an on-demand presentation and one-on-one meetings with Chief Financial Officer Gilad Mamlok. The presentation becomes available on September 13 at 7 a.m. ET. Sol-Gel specializes in developing topical drug products for skin diseases, including FDA-approved TWYNEO for acne treatment. Their pipeline includes EPSOLAY for rosacea, with a pending NDA, as well as candidates SGT-210, SGT-310, and SGT-510 for various skin conditions.
Sol-Gel Technologies (NASDAQ: SLGL) announced FDA approval of TWYNEO® for acne treatment, triggering an $8 million milestone payment from Galderma. The company signed exclusive licensing agreements for TWYNEO® and EPSOLAY®, which is pending FDA action. Second quarter 2021 revenue was $0.9 million, down from $1.1 million in 2020. Research and development costs increased to $6.9 million, while general and administrative costs decreased to $2.0 million. The company reported a net loss of $8.0 million for the quarter and has $38.9 million in cash and securities to fund operations through early 2023.
Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) announced FDA approval for TWYNEO, a once-daily cream for acne vulgaris, combining tretinoin and benzoyl peroxide. This marks the first FDA-approved fixed-dose combination for this treatment, utilizing proprietary microencapsulation technology. TWYNEO is patent protected until 2038. Sol-Gel is set to receive a regulatory milestone payment from Galderma, its U.S. commercialization partner, and retains an option for commercialization rights after five years. The drug is expected to significantly impact the treatment landscape for acne patients.
Sol-Gel Technologies (Nasdaq: SLGL) will report its second quarter 2021 financial results on August 4, 2021, at 7:05 AM ET. The company focuses on developing topical drug products for skin diseases, utilizing its microencapsulation technology platform. TWYNEO and EPSOLAY are under investigation for acne and rosacea, respectively, with NDAs filed with the FDA. However, the approval for EPSOLAY is delayed due to COVID-19 travel restrictions affecting the FDA's inspection of the production site.